# Arianna Ghirardi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/arianna-ghirardi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,483 |
| Field | Myeloproliferative Neoplasms: Diagnosis and Treatment |
| h-index | 20 |
| i10-index | 29 |
| Last Known Institution | University of Bergamo |
| OpenAlex ID | https://openalex.org/A5063850306 |
| ORCID iD | 0000-0001-9391-6963 |
| Works | 72 |

## Researcher papers

Showing 12 of 13.

- [Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis](https://scholariq.org/papers/leukocytosis-and-thrombosis-in-essential-thrombocythemia-and-polycythemia-vera-a/)
- [Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial](https://scholariq.org/papers/ropeginterferon-alfa-2b-versus-phlebotomy-in-low-risk-patients-with/)
- [Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study](https://scholariq.org/papers/second-cancer-in-philadelphia-negative-myeloproliferative-neoplasms-mpn-k-a/)
- [Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study](https://scholariq.org/papers/covid-19-and-gender-lower-rate-but-same-mortality-of-severe-disease-in-women-an/)
- [A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: A propensity‐matched study](https://scholariq.org/papers/a-reappraisal-of-the-benefit-risk-profile-of-hydroxyurea-in-polycythemia-vera-a/)
- [High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib](https://scholariq.org/papers/high-mortality-rate-in-covid-19-patients-with-myeloproliferative-neoplasms-after/)
- [Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases](https://scholariq.org/papers/hydroxyurea-prevents-arterial-and-late-venous-thrombotic-recurrences-in-patients/)
- [Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis](https://scholariq.org/papers/ruxolitinib-for-the-prevention-of-thrombosis-in-polycythemia-vera-a-systematic/)
- [Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study](https://scholariq.org/papers/impact-of-ruxolitinib-on-survival-of-patients-with-myelofibrosis-in-the-real/)
- [Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis](https://scholariq.org/papers/clinical-outcomes-under-hydroxyurea-treatment-in-polycythemia-vera-a-systematic/)
- [Predictors of response and enteral autonomy in children with short bowel syndrome treated with teduglutide: a real-life multicentre cohort study](https://scholariq.org/papers/predictors-of-response-and-enteral-autonomy-in-children-with-short-bowel/)
- [85: PRELIMINARY RESULTS OF THE REGISTRY OF EUROPEAN CHILDREN TREATED WITH TEDUGLUTIDE](https://scholariq.org/papers/85-preliminary-results-of-the-registry-of-european-children-treated-with/)

## Researcher topics

- [Myeloproliferative Neoplasms: Diagnosis and Treatment](https://scholariq.org/topics/myeloproliferative-neoplasms-diagnosis-and-treatment/)
- [Eosinophilic Disorders and Syndromes](https://scholariq.org/topics/eosinophilic-disorders-and-syndromes/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Hemoglobinopathies and Related Disorders](https://scholariq.org/topics/hemoglobinopathies-and-related-disorders/)
- [Kruppel-like factors research](https://scholariq.org/topics/kruppel-like-factors-research/)

## Researcher university

- [University of Bergamo](https://scholariq.org/institutions/university-of-bergamo/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.